Enzyme
Summer 2017AcquiredAutomating regulatory approval & compliance for life science companies
Pressure-test this opportunity
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Automating regulatory approval & compliance for life science companies
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Enzyme built an electronic quality-management system for life-science companies from 2017 until Greenlight Guru acquired it in July 2025. [7] The product joined document control, training, design controls, risk, audits, complaints, nonconformance, CAPA, and regulatory consulting in one system. Its first wedge was unusually concrete: connect the engineering tools a startup already used and turn the work into inspection-ready evidence. [1] [6]
Enzyme proved that small medical-device teams would buy a friendlier QMS, attracted a public-company majority shareholder, and survived into a strategic acquisition. [3] The constraint appeared after validation: regulated software creates an expanding obligation to maintain infrastructure, support, validation, and domain expertise. In that market, the installed base and operating capacity of a broader platform eventually mattered more than an independent product's elegance.
Image 1 / 2
Jared Seehafer and Jacob Graham had spent years doing the work Enzyme would later encode. Seehafer's background included product and regulatory roles at St. Jude Neuromodulation and Medtronic Diabetes. He held an MS in Medical Device Engineering from USC and a Regulatory Affairs Certification. [5] Graham spent more than a decade in medical-device engineering, design assurance, and quality systems at Boston Scientific, Medtronic, and a startup. [3]
Their complaints came from opposite sides of the same process. Seehafer had co-founded a consulting firm that helped companies prepare submissions. Graham had watched quality work fragment across disconnected enterprise systems. The company's public handbook described delays of weeks or months when people lacked access to one of those systems or used it too infrequently to work efficiently. [4]
In 2016, Seehafer approached his friend with the idea for one cloud application. Graham recalled: "I would routinely log into 4–6 different technology platforms for training, performance, compliance, and more, and I knew there had to be a more streamlined way." He said their backgrounds fit because his workflow knowledge complemented Seehafer's medical-device and software experience. [3]
Seehafer put the founding insight more bluntly in a 2018 TechCrunch interview: "You find you spend almost as much time documenting the work as you do doing the work." He followed it with the question that became the product thesis: "This is a multitrillion-dollar industry and I thought 'why isn't there software to automate the process?'" [2]
Enzyme launched in 2017 and joined YC's Summer batch. Refactor Capital said the founders' direct knowledge of the regulatory maze was central to its investment thesis. [10]
Enzyme started with a useful distinction: engineering teams already produced much of the evidence regulators needed, but the evidence lived in tools built for shipping software rather than defending a quality system. Its early product connected Jira, Trello, and GitHub so a startup did not need to copy the same work into a separate compliance system. [2]
The product expanded into a modular eQMS. Its core covered controlled documents, training, electronic signatures, and integrations. Premarket work added design controls, risk management, and supplier records. Postmarket work covered audits, complaints, nonconformance, and corrective and preventive actions. Enzyme also listed an electronic trial master file module. Customers chose Core, Premarket, or Postmarket packages and paid according to both plan and user type; Lite users could view materials and sign off on training, while Full users operated the system. [6]
Software was only part of the offer. Enzyme sold a library of compliant procedures plus Quality as a Service and Regulatory as a Service. Consultants helped companies establish a QMS, train employees, prepare for FDA or notified-body audits, and assemble pre-submissions and full submissions. [4] That hybrid mattered because a blank workflow engine cannot tell a first-time founder which controls apply.
The company also described machine learning and natural-language processing as tools for generating documents from existing work. [4] The public evidence does not show how much of that automation shipped, so it is safer to judge Enzyme by the workflow product and service layer that customers could buy.
Enzyme began with early-funded digital-health and medical-device startups. Seehafer sought partnerships with accelerators and venture firms because those organizations could introduce companies just as regulatory work became urgent. [2] The later product stretched toward larger life-science organizations, but its plainest advantage remained a system that novices could use without stripping out the controls experienced quality teams needed.
Enzyme did not publish a defensible addressable-market estimate. Public evidence offers better demand signals than a top-down number. It had about 10 customers six months after beta and later attracted Roivant as majority shareholder. [2] One 2023 customer claim said Enzyme reduced the interval between completed code and deployment from eight weeks to two. [3]
Competitor financing shows how much capital entered the category. Qualio announced an $11 million Series A in 2020 and a $50 million Series B in 2021. [13] That money funded product development and global expansion, raising the cost of competing for product breadth and enterprise trust.
Enzyme competed first against spreadsheets, document repositories, consultants, and general work trackers. That fragmented baseline made integration a strong wedge. It also competed against purpose-built vendors such as Qualio and Greenlight Guru, whose larger funding or installed bases supported more modules, implementation resources, and educational distribution.
Greenlight Guru illustrates the category's direction. Before buying Enzyme, it had acquired clinical-data vendor SMART-TRIAL and data consultancy Vertex Intelligence. [9] At the Enzyme deal it said it served more than 1,100 medical-device companies and had acquired Ultralight Labs only weeks earlier. [8] The market was consolidating around suites that could cover quality, risk, clinical, and postmarket work.
Enzyme combined subscription software with expert services. Plans varied by lifecycle scope and by Full versus Lite users. Pricing was quote-based, and public materials did not disclose contract values, gross margin, revenue, retention, or profitability. [6]
The services layer probably eased adoption and increased initial contract value, but it also tied growth to scarce regulatory expertise. That is an inference from the product mix, not a disclosed unit-economics result. The last public financing figure was $1.85 million in January 2018 from Refactor Capital, Data Collective, Soma Capital, Rock Health, and angels. [2] Roivant's later majority purchase supplied a second form of capital, though its terms were not published.
Enzyme reported about 10 customers in January 2018. By 2023 it could point to a customer that cut the code-complete-to-deployment interval from eight weeks to two, a 75% reduction in elapsed time if the endpoints are comparable. [2] [3]
The two ownership events are stronger evidence of strategic value than any undisclosed revenue estimate. Roivant became majority shareholder in 2022; Greenlight Guru then bought the company in 2025 and began moving customers onto a continuity and support roadmap. [8]
Enzyme's acquisition announcement names the primary constraint. Seehafer wrote that meeting customers' evolving needs "requires a more mature infrastructure." [7] In regulated software, infrastructure means more than uptime. Every module expands the validation surface, audit trail, support burden, regulatory maintenance, and implementation work.
The team addressed that burden in stages. Roivant became majority shareholder in 2022 while Enzyme stayed independent. Three years later, Seehafer chose to leave and sought a larger operating home. Greenlight Guru offered customer support, an installed base, and a broader lifecycle platform. The remedy succeeded as an acquisition, but it ended Enzyme as an independent company.
The 2022 share purchase showed that Enzyme could attract strategic capital. It did not give the company the category-wide distribution of a dedicated eQMS platform. That interpretation fits the 2025 buyer: Greenlight Guru already served more than 1,100 device companies and had assembled quality, clinical-data, and analytics capabilities through acquisitions. [8]
Enzyme's attempted remedy was sensible: remain independent under a life-science majority shareholder and keep building. The eventual outcome suggests capital alone did not remove the operating disadvantage. In a trust-heavy market, distribution and support capacity compound because each successful implementation becomes a reference, each regulatory update can be spread across more customers, and each adjacent module raises switching costs.
Greenlight Guru framed the deal around Seehafer's career decision and continuity for Enzyme's customers. [8] Its announcement did not disclose a price, and no public source establishes investor returns, so calling the exit either a blockbuster or a distressed sale would overstate the record.
An acquisition after eight operating years is a successful exit under a reasonable reading. The useful lesson is narrower. The founding wedge worked, but the company entered a category where a successful narrow product creates pressure to become a broad, permanently maintained system of record. Enzyme's exit shows where that pressure led.